Technical Analysis for FNCH - Finch Therapeutics Group, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.10 | -0.75% | -0.02 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hammer Candlestick | Bullish | -0.75% | |
| Narrow Range Bar | Range Contraction | -0.75% | |
| Wide Bands | Range Expansion | -0.75% | |
| Down 3 Days in a Row | Weakness | -0.75% | |
| Down 4 Days in a Row | Weakness | -0.75% | |
| Oversold Stochastic | Weakness | -0.75% | |
| Narrow Range Bar | Range Contraction | -3.49% | |
| Stochastic Reached Oversold | Weakness | -3.49% | |
| Wide Bands | Range Expansion | -3.49% | |
| Down 3 Days in a Row | Weakness | -3.49% |
| Alert | Time |
|---|---|
| Down 3% | 27 minutes ago |
| Down 2 % | 27 minutes ago |
| Down 1% | 37 minutes ago |
| Down 5% | about 20 hours ago |
| 60 Minute Opening Range Breakdown | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/09/2023
Finch Therapeutics Group, Inc. Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Autoimmune Disease Infection Specialty Drugs Ulcerative Colitis Abdominal Pain Colitis Crohn's Disease Diarrhea Autism Spectrum Disorder Chronic Hepatitis B Virus Clostridioides Difficile Treatment Of Autism Spectrum Disorder University Of Minnesota
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.74 |
| 52 Week Low | 1.86 |
| Average Volume | 61,499 |
| 200-Day Moving Average | 4.01 |
| 50-Day Moving Average | 2.49 |
| 20-Day Moving Average | 2.35 |
| 10-Day Moving Average | 2.27 |
| Average True Range | 0.34 |
| RSI (14) | 43.82 |
| ADX | 26.42 |
| +DI | 25.31 |
| -DI | 16.81 |
| Chandelier Exit (Long, 3 ATRs) | 2.36 |
| Chandelier Exit (Short, 3 ATRs) | 2.87 |
| Upper Bollinger Bands | 2.81 |
| Lower Bollinger Band | 1.89 |
| Percent B (%b) | 0.25 |
| BandWidth | 39.23 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.06 |
| MACD Histogram | -0.0152 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.29 | ||||
| Resistance 3 (R3) | 2.28 | 2.22 | 2.26 | ||
| Resistance 2 (R2) | 2.22 | 2.18 | 2.22 | 2.25 | |
| Resistance 1 (R1) | 2.17 | 2.15 | 2.14 | 2.18 | 2.24 |
| Pivot Point | 2.11 | 2.11 | 2.10 | 2.11 | 2.11 |
| Support 1 (S1) | 2.06 | 2.07 | 2.03 | 2.07 | 2.00 |
| Support 2 (S2) | 2.00 | 2.04 | 2.00 | 1.99 | |
| Support 3 (S3) | 1.95 | 2.00 | 1.98 | ||
| Support 4 (S4) | 1.96 |
